InvestorsHub Logo
Followers 19
Posts 817
Boards Moderated 0
Alias Born 12/12/2016

Re: jimmy667 post# 1776

Wednesday, 11/13/2019 7:59:06 PM

Wednesday, November 13, 2019 7:59:06 PM

Post# of 1856
Strong move recently; thanks Jimmy667 for the tip last year around $12/share.

Last quarterly call was impressive as well.

https://www.google.com/amp/s/www.fool.com/amp/earnings/call-transcripts/2019/08/05/arrowhead-research-corp-arwr-q3-2019-earnings-call.aspx


“Arrowhead price target raised to $59 from $46 at B. Riley FBR B. Riley FBR analyst Mayank Mamtani raised his price target for Arrowhead Pharmaceuticals to $59 from $46 after hosting meetings with management. The Landsat came away "incrementally encouraged" with the strength of data being presented for Arrowhead's three lead RNAi programs "aimed at large population diseases," including hepatitis B and mixed dyslipidemia. He sees a "healthy catalyst profile" for Arrowhead shares and reiterates a Buy rating on the name.”

Read more at:

https://thefly.com/permalinks/entry.php/id2993375/ARWR-Arrowhead-price-target-raised-to--from--at-B-Riley-FBR
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ARWR News